Sandbox Reserved 1739

/>

Function

The function of Hepatitis C primase is to build the viral capsid. The viral capsid and two glycoproteins make up the genome (1). The function of Hepatitis C helicase is to stop viral RNA from binding by stripping it of its proteins. It is necessary for viral replication (2). Helicase can process a wide range of nucleic acid sequences and unwind them (5). Together, Hepatitis C primase and helicase functions together are still undetermined.

Disease

Hepatitis C (HCV) is a viral infection that causes inflammation of the liver. As of 2022 there has been no vaccine created for Hepatitis C (6). HCV was originally thought as a putative viral hepatitis that developed after some sort of blood transfusion of intravenous drug usage. Hepatitis C virus causes large amounts of damage to the liver, disrupting normal liver function and damaging the quality of life for the patient, due to the normal progression of the infection. Development of hepatitis C is expected to progress to chronic liver disease, cirrhosis, and other hepatocellular carcinomas. HCV is shown to be the leading cause of chronic liver disease in both industrialized and developing countries (11). Acute HCV is clinically mild and normally unrecognized and undiagnosed due to the insignificance of the symptoms. The introductory warnings are flu-like symptoms which are not significant to HCV in particular, as flu-like symptoms are shared with many acute viral infections. More tell-tale symptoms are dark urine, anorexia, jaundice, and abdominal discomfort. The public that is more prone to become infected with HCV are healthcare workers, dialysis patients, intravenous drug users, people who received a blood product before routine screening of blood for hepatitis C (before 1990), and groups participating in high-exposure sexual activities. HCV is spread through infected blood. HCV is not particularly treatable, but spontaneous clearance of the disease is very possible in acute HCV. Studies have shown that acute HCV is cleared and does not progress to chronic illness in 15-40% of cases (11). Factors that influence clearance of the disease from happening are immune system response, manner of infection, immunosuppression by external factors, severity of the illness, HIV co-infection, and many other aspects. The other spectrum of hepatitis C virus is Chronic HCV, which is the long-term progression of the disease. Chronic HCV is the leading cause of end-stage liver disease, hepatocellular carcinoma and liver related deaths in the Western world (11). Chronic HCV is defined by persistent hepatic inflammation, which generally leads to the development of scarring of the liver which greatly impacts the function of the liver. Patients being unaware of the development of chronic HCV is prevalent until end stage liver disease or failure due to the common symptoms with acute and chronic HCV. There are many factors that can aid in the advancement of chronic HCV, examples being age at infection, gender (more frequent in males), immunosuppressive therapy, genetic factors, insulin resistance, obesity, and other immunocompromising diseases. Although spontaneous clearance of the disease is common in the acute stage of HCV, it is far less common in the chronic stage.

Relevance

The relevance of Hepatitis C helicase/primase is that the helicase/protease combination in HCV is believed to play a pivotal role in the replication cycle of HCV. The helicase exists as a dimer, bearing mutations, and can be found in three different functional states (9). The three functional states include a substrate-unbound state, an ATP-bound state, and an NA-bound state. The presence of ATP transitions the protease from high NA binding affinity to low NA binding affinity. The cooperation of helicase/protease binding the DNA is affected by the length of the ss lattice, and the desired ss DNA length is around 22nt (3).

Structural highlights

2OBQ: for Hepatitis primase Method: X-Ray Diffraction. Resolution: 2.50 Å. Classification: Viral Protein. Organism(s): Hepacivirus C. Expression System: Escherichia coli. Deposited: 2006-12-19. Released: 2007-07-31. Deposition Author(s): Prongay, A.J., Guo, Z., Yao, N., Fischmann, T., Strickland, C., Myers Jr., J., Weber, P.C., Malcolm, B., Beyer, B.M., Ingram, R., Pichardo, J., Hong, Z., Prosise, W.W., Ramanathan, L., Taremi, S.S., Yarosh-Tomaine, T., Zhang, R., Senior, M., Yang, R., Arasappan, A., Bennett, F., Bogen, S.F., Chen, K., Jao, E., Liu, Y., Love, R.G., Saksena, A.K., Venkatraman, S., Girijavallabhan, V., Njoroge, F.G., Madison, V. Primary Structure: 180 amino acids. Secondary Structure: three alpha helices with 2 connecting loops. 9 anti-parallel beta sheets. Mixed barrel (13). Tertiary Structure: